((1-Chloro-2-methylpropan-2-yl)oxy)trimethylsilane is an intermediate for the synthesis of 3-Hydroxy Bortezomib (H818150), which is a metabolite of Bortezomib (B675700); the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.